Portal de Periódicos da CAPES

P1.21-07 Quantitative Assessment of OX40L and Its Association with Sensitivity to First-Line Pembrolizumab in Non-small-Cell Lung Cancer

2023; Elsevier BV; Volume: 18; Issue: 11 Linguagem: Inglês

10.1016/j.jtho.2023.09.393

1556-1380

José Manuel Baena, Antonio Calles, Carlos Aguado, Mónica Antoñanzas, Y. Lage, María Sereno, Xabier Mielgo-Rubio, Anna Mar López, Raimundo Cervera, Luís Cabezón-Gutiérrez, Judit Rubio, M.V. Sanchez-Becerra, Magdalena Molero-Abraham, Melina Peressini, Gorka Ruíz de Garibay, C. Fernández-Luna, Vera Adradas, Mercedes Herrera, Horacio Cabo, Rosa Álvarez, Pilar Garrido, J.L. González-Larriba, Fernando López-Rı́os, Esther Conde, Luis Paz‐Ares, Jon Zugazagoitia,

Immune cells in cancer

Despite the unprecedented survival benefit of PD-1 axis blockade in advanced non-small-cell lung cancer (NSCLC), most patients fail to achieve durable responses with monotherapies, even in the presence of high PD-L1 expression. In this study, we aimed to uncover spatially resolved protein markers associated with sensitivity to single-agent PD-1 axis inhibition in the setting of treatment naïve, high PD-L1 expressing, NSCLC patients.